- 27 March
-
A meeting of the Committee on Entrepreneurship in Healthcare and Medical Industry of the Ural Chamber of Commerce and Industry was held in Ekaterinburg on March 18, 2025, chaired by Alexander Petrov. Participants of the event, including representatives of the Association of Medical Specialists for Risk Modification, the Association of Medical and Pharmaceutical Manufacturers of the Sverdlovsk Region, the Ural Biomedical Cluster and members of the Committee considered key challenges in maintaining the health of the able-bodied population, fighting against socially significant diseases and regulating prices for vital drugs.
- 05 December
-
The Russian pharmaceutical industry has gained significant stability in the recent years thanks to manufacturers such as Medsintez Plant. This is a modern full-cycle biotechnological enterprise that develops and manufactures pharmaceutical ingredients and drugs that meet international GMP and ISO standards.
- 27 September
-
On September 26, 2024, TASS hosted an expert discussion in the format of a federal teleconference Moscow-St. Petersburg-Ekaterinburg-Novosibirsk-Vologda-Anapa, dedicated to discussing the role, reasons and mechanisms for stimulating In Ekaterinburg, Alexander Petrov, the Chairman of the Board of Directors of Medsintez Plant LLC, told the participants about Triazavirin, an innovative domestic antiviral drug, as a success case of private investment in science.
- 07 September
-
60 leading Russian reproductologists visited the pharmaceutical company Medsintez Plant in Novouralsk on September 4, 2024. This event was timed to coincide with the celebration of the 3rd anniversary of the opening of the production workshop for biotechnological substances for the reproductive health of women, as well as the Annual International Conference «Reproductive Technologies Today and Tomorrow» in Ekaterinburg. Leading experts and conference speakers visited the production of the first Russian follitropin alpha for the treatment of human infertility, Primapur®.
- Home
- Cluster members
- URAL NANOTECHNOLOGY CENTER, LLC
URAL NANOTECHNOLOGY CENTER, LLC
URAL NANOTECHNOLOGY CENTER, LLC is a developer and manufacturer of unique innovative products under DEZITOL trademark.
The main activity of the company is production of high quality products based on unique innovative solutions for the Russian and international markets. DEZITOL products are designed to protect against transmission and development of infections, and are successfully used in various areas with higher sanitary requirements, such as medicine and agriculture, and others. Currently, DEZITOL product line includes
Disinfectant (skin antiseptic) DEZITOL A
Skin antiseptic based on isopropyl alcohol for hand treatment, including hands of surgeons, operating field, injection field, gloves on the hands of medical personnel (in accordance with the instructions for use). Having high antimicrobial activity, it is gentle for skin. Effective against pathogens of healthcare-associated infections and Mycobacterium tuberculosis (tested on Mycobacterium terrae).
Passed tests at Disinfectology Research Institute of the Federal Service for the Oversight of Consumer Protection and Welfare.
Effective against pathogens of healthcare-associated infections and Mycobacterium tuberculosis (tested on Mycobacterium terrae).
It is intended for hygienic treatment of hands of personnel at industrial enterprises, catering facilities, municipal facilities, sanitary inspection checkpoints, hairdressing salons, beauty salons, etc.
In accordance with the letter of the Federal Budgetary Institution of Science Disinfectology Research Institute of the Federal Service for the Oversight of Consumer Protection and Welfare ref. No. 77-53-02/468-2020.1.15 dated April 23, 2020, formula of the skin antiseptic DEZITOL A allows application thereof to prevent coronavirus COVID-19 and other viral infections.
Antimicrobial preventive coating DEZITOL B
Innovative product for long- term antimicrobial skin protection. The use thereof in surgical hospitals allows for multi- barrier protection of a patient against pathogenic microflora during operative time and postoperative periods.
DEZITOL B is used on operative field to create a protective incise drape, as well as to close the postoperative wound, to increase comfort of the patient's stay in the hospital due to a possibility of non- dressing treatment of the postoperative wound.
Also, this product is actively used by the population in everyday life as a «Liquid bandage» to close small scratches, small superficial and postoperative wounds, preventing bedsores up to the stage II, protecting the skin around fistulas and stoma.
Protective coating DEZITOL C
A unique development of the Urals scientists — a coating with no analogues in the world. Designed to create a protective coating on surrounding surfaces with a long-lasting antimicrobial effect (up to 12 months).
All products have passed the required tests and are registered. Protective coating DEZITOL C successfully confirmed the declared characteristics in independent accredited laboratories of the European Union countries and the Arab Republic of Egypt.
Currently, the manufactured products have successfully passed long-term full-scale tests and are actively used in medical institutions of the Russian Federation.
Production technology of DEZITOL products is fully automated and complies with GOST ISO 13485-2017 “International Standard. Medical products. Quality management systems. Requirements for Regulatory Purposes” and ISO 9001:2015 “Quality Management Systems. Requirements".
Tel. 8-800-775-52-55 (within Russia calls are free)
E-mail: info@dezitall.ru
